These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35023374)

  • 1. Pharmacogenetics of HIV therapy: challenges for tailoring treatment in genetically complex populations.
    de Almeida Velozo C; Cardoso CC
    Pharmacogenomics; 2022 Feb; 23(3):157-159. PubMed ID: 35023374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
    Kwara A
    Pharmacogenomics; 2021 Sep; 22(14):881-884. PubMed ID: 34505542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic considerations in the treatment of HIV.
    Mattevi VS; Tagliari CF
    Pharmacogenomics; 2017 Jan; 18(1):85-98. PubMed ID: 27976978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.
    Neary M; Owen A
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1169-1181. PubMed ID: 28994310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
    Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic Markers: A Path toward Individualized HIV Therapy.
    García-Blanco D; Gravier-Hernández R; Rabeiro-Martínez CL; Gil Del Valle L; Pérez-Ávila J
    MEDICC Rev; 2019; 21(2-3):59-68. PubMed ID: 31401638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.
    Yu ZJ; Mosher EP; Bumpus NN
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():565-585. PubMed ID: 32960701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
    Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
    Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward genetic rationalization of antiretroviral therapy for HIV.
    Schwartz DH; Iyengar S
    AIDS; 2005 Jun; 19(9):975-7. PubMed ID: 15905680
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenetics. Tailored therapy in medicine -- opportunities and challenges].
    Scharplatz M; Puhan M; Steurer J; Bachmann LM
    Praxis (Bern 1994); 2004 Mar; 93(10):359-65. PubMed ID: 15052854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
    Olagunju A; Bolaji O; Amara A; Waitt C; Else L; Adejuyigbe E; Siccardi M; Back D; Khoo S; Owen A
    Clin Infect Dis; 2015 Aug; 61(3):453-63. PubMed ID: 25882300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy.
    Telenti A
    Pharmacogenomics; 2009 Apr; 10(4):515-6. PubMed ID: 19374508
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
    Arab-Alameddine M; Di Iulio J; Buclin T; Rotger M; Lubomirov R; Cavassini M; Fayet A; Décosterd LA; Eap CB; Biollaz J; Telenti A; Csajka C;
    Clin Pharmacol Ther; 2009 May; 85(5):485-94. PubMed ID: 19225447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.